Carna Biosciences,Inc. Board Supports

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on January 29, 2026. It represents a primary source document for Japanese M&A sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Carna Biosciences,Inc. Board Supports Tender Offer, Recommends Shareholders Tender

Source disclosure: January 29, 2026 Carna Biosciences,Inc. [4572.T] TOKYO — Carna Biosciences, Inc., represented by President and CEO Koichiro Yoshino (stock code: 4572), announced on January 29 that its board has resolved to repurchase and cancel all outstanding shares of its First Tranche Convertible Bond with Warrant attached issued on July 11, 2025. The company also decided to issue new unsecured bonds and warrants through a private placement to Cantor Fitzgerald Europe. The dec